×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

PDE1ÊÇÓëÖÐÊàºÍÍâÖܼ²²¡Ç×½üÏà¹ØµÄÒ©Îï°Ðµã£¬Ñо¿Ö°Ô±ºÏ³ÉÒ»ÖÖPDE1 ÒÖÖÆ¼ÁÔÚ´óÊó¸Î΢Á£ÌåÖоßÓÐÓÅÒìµÄ´úлÎȹÌÐÔ¡£ÆäÖÐÎȹÌÐÔ²âÊÔͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ

2023-07-06
|
»á¼ûÁ¿£º

Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat liver microsomes. Stability test in the rat liver microsomes were performed by Medicilon.

61.jpg

Reference:

Bei Zhang, et al. Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors. Bioorg Chem. 2021 Sep;114:105104. doi: 10.1016/j.bioorg.2021.105104. 

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿